CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 163 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,352,481 | +518.5% | 158,157 | +662.6% | 0.00% | – |
| Q2 2023 | $703,708 | +28954.8% | 20,740 | -61.8% | 0.00% | -100.0% |
| Q4 2022 | $2,422 | -100.0% | 54,351 | -79.1% | 0.00% | -75.0% |
| Q2 2022 | $6,998,000 | +90.8% | 259,543 | +141.0% | 0.00% | +100.0% |
| Q1 2022 | $3,668,000 | +139.3% | 107,701 | +171.5% | 0.00% | +100.0% |
| Q4 2021 | $1,533,000 | -85.3% | 39,671 | -92.1% | 0.00% | -85.7% |
| Q1 2021 | $10,406,000 | +188.4% | 505,163 | +145.3% | 0.01% | +133.3% |
| Q4 2020 | $3,608,000 | -39.9% | 205,922 | -55.4% | 0.00% | -66.7% |
| Q2 2020 | $6,003,000 | – | 461,764 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |